VEGFC and early-onset autosomal dominant Alzheimer disease: Moreover, this therapeutic concept may be applicable to other neurological disorders that have been shown to respond to VEGF-C-induced mLV activation, such as Alzheimer’s disease, Parkinson’s disease and multiple sclerosis26,27,29,33,34.